EvaluateMedTech World Preview 2017, Outlook to 2022

Worldwide Medtech Sales Forecast to Reach $522 Billion by 2022 with a CAGR of 5.1% between 2016 and 2022

The new edition of EvaluateMedTech World Preview 2017, Outlook to 2022 shows Medtronic was the leading medtech company in 2016 with sales of almost $30bn. They will retain the crown in 2022 with sales forecast to reach $37.7bn.

Our annual report highlights trends in medtech including: consensus sales forecasts of leading industry analysts by device area to 2022; the top 20 companies in 2022; R&D spend current and future; FDA approvals; M&A; venture financing; IPOs; and enterprise value.

Key Highlights

  • Total value of medtech M&A deals rises by a massive 178% in H1 2017

  • In vitro diagnostics is expected to remain the largest medtech segment in 2022 with annual sales of $70bn; Roche remains top player with expected sales of $12.8bn in 2022

  • Total value of medtech venture financing deals rises 56% in H1 2017 despite the number of deals falling by 11%

  • Total value of medtech IPOs continues to fall in H1 2017 to $122m

View EvaluateMedTech World Preview 2017, Outlook to 2022 Executive Summary

This analysis is based on in-depth consensus forecast models for the top 300 global medtech companies available within the EvaluateMedTech service.